Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Wierda

Showing results (151-160 of 181) with videos related to

Pageof 19
Sort By:
Haematologica|September 2, 2017
Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patientsNitin Jain, Xinyan Lu, Naval Daver, et al.
American Journal of Hematology|January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agentsElias Jabbour, Paolo Strati, Monica Cabrero, et al.
Nature Reviews. Clinical Oncology|September 20, 2017
Chimeric antigen receptor T-cell therapy - assessment and management of toxicitiesSattva S Neelapu, Sudhakar Tummala, Partow Kebriaei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylateHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
American Journal of Hematology|November 5, 2019
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survivalMusa Yilmaz, Hagop Kantarjian, Xuemei Wang, et al.
The Lancet. Haematology|May 15, 2023
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trialElias Jabbour, Nicholas J Short, Jayastu Senapati, et al.
The Lancet. Oncology|October 4, 2015
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 studyElias Jabbour, Hagop Kantarjian, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignanciesKaren W L Yee, Anne Hagey, Srdan Verstovsek, et al.
The Lancet. Oncology|January 21, 2018
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 studyHagop Kantarjian, Farhad Ravandi, Nicholas J Short, et al.
Frontiers in Immunology|January 31, 2018
The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by LenalidomideHila Shaim, Zeev Estrov, David Harris, et al.
Pageof 19

Showing results (151-160 of 181) with videos related to

Sort By:
Pageof 19
Haematologica|September 2, 2017
Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patientsNitin Jain, Xinyan Lu, Naval Daver, et al.
American Journal of Hematology|January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agentsElias Jabbour, Paolo Strati, Monica Cabrero, et al.
Nature Reviews. Clinical Oncology|September 20, 2017
Chimeric antigen receptor T-cell therapy - assessment and management of toxicitiesSattva S Neelapu, Sudhakar Tummala, Partow Kebriaei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylateHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
American Journal of Hematology|November 5, 2019
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survivalMusa Yilmaz, Hagop Kantarjian, Xuemei Wang, et al.
The Lancet. Haematology|May 15, 2023
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trialElias Jabbour, Nicholas J Short, Jayastu Senapati, et al.
The Lancet. Oncology|October 4, 2015
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 studyElias Jabbour, Hagop Kantarjian, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignanciesKaren W L Yee, Anne Hagey, Srdan Verstovsek, et al.
The Lancet. Oncology|January 21, 2018
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 studyHagop Kantarjian, Farhad Ravandi, Nicholas J Short, et al.
Frontiers in Immunology|January 31, 2018
The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by LenalidomideHila Shaim, Zeev Estrov, David Harris, et al.
Pageof 19